Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA

Blood

Volumn 97, Issue 5, 2001, Pages 1258-1265

  Nathwani, Amit C ^a   Davidoff, Andrew ^a   Hanawa, Hideki ^a   Zhou, Jun Fang ^a   Vanin, Eno F ^a   Nienhuis, Arthur W ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 9; COMPLEMENTARY DNA; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CYTOMEGALOVIRUS; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; INJECTION SITE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0035282898     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.5.1258     Document Type: Article

References (41)

1. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
2. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy
3. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
4. Persistent expression of canine factor IX in hemophilia B canines
5. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver
6. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector
7. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
8. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
9. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia
10. Characterization of B- and T-cell response against factor IX in AAV vector-based gene therapy for canine hemophilia B
11. Immune response in hemophilia B mice expressing a species specific transgene
12. Efficient selection for high-expression transfectants with a novel eukaryotic vector
13. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication
14. An ex vivo keratinocyte model for gene therapy of hemophilia B
15. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo
16. +
17. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus
18. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses
19. Human hepatoma cells secrete single chain factor X, prothrombin, and antithrombin III
20. High-efficiency retroviral infection of primary myoblasts
21. Adenovirus-mediated gene transfer: Influence of transgene, mouse strain and type of immune response on persistence of transgene expression
22. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains
23. In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs
24. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression
25. Human factor IX corrects the bleeding diathesis of mice with hemophilia B
26. Role of intron I in expression of the human factor IX gene
27. Characterization of recombinant human factor IX expressed in transgenic mice and in derived trans-immortalized hepatic cell lines
28. Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice
29. Evaluation of HBV promoters for use in hepatic gene therapy
30. Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes
31. The kinetics of rAAV integration in the liver
32. HBV-derived promoters direct liver-specific expression of an adenovirally transduced LDL receptor gene
33. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver
34. + hematopoietic progenitor cells: Donor variation and correlation of transgene expression with cellular differentiation
35. Factor IX synthesized in dog and human muscle cells has specific activity comparable to plasma-derived factor IX
36. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors
37. Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver
38. Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: Cell cycling does not influence hepatocyte transduction
39. Immune responses to adenovirus and adeno-associated virus in humans
40. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle
41. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes